ScreenerHero

OSTX OS Therapies Incorporated

AMEX · US · Healthcare · Biotechnology · ostherapies.com
1.550USD+4.03%Mkt Cap: 72.55M $P/E: —

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. The com…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap72.55M USD
Enterprise Value69.59M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-28.75M USD
Revenue/Share—
Last Price1.550 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees4
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)4.30
PEG—
EV/EBITDA-1.88
EV/Revenue—
P/S—
P/B-5.67
EPS (TTM)-1.01
EPS (Forward)0.35
52W Range
1.15036% of range2.250
52W High2.250 USD
52W Low1.150 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE471.71%
ROA-420.41%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-14.24M USD
CapEx (TTM)466.42K USD
FCF Margin—
FCF Yield-2.33%
Net Debt-205.03K USD
Net Debt/EBITDA0.01
Balance Sheet
Debt/Equity—
Current Ratio0.18
Quick Ratio0.16
Book Value/Sh-0.26 USD
Cash/Share0.0040 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)8.500 USD
Upside (mean)+448.4%
Target Range6.000 USD – 13.00 USD
6.000+448.4% to mean13.00
# Analysts4
Ownership
Shares Out.46.81M
Float40.41M
Insiders21.06%
Institutions6.21%
Short Interest
Short Ratio3.4d
Short % Float4.85%
Short % Out.4.52%
Shares Short2.11M
Short (prev mo.)2.58M
Technical
SMA 501.646 (-5.9%)
SMA 2001.577 (-1.7%)
Beta-0.64
S&P 52W Chg15.77%
Avg Vol (30d)772.59K
Avg Vol (10d)411.40K
Technical Indicators
RSI (14)41.6
MACD-0.0332
MACD Signal-0.0098
MACD Hist.-0.0234
BB Upper1.900 USD
BB Middle1.690 USD
BB Lower1.481 USD
BB Width24.76%
ATR (14)0.1062 USD
Vol Ratio (20d)0.66x